Your browser doesn't support javascript.
loading
Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice.
Melzi, Eleonora; Willis, Jordan R; Ma, Krystal M; Lin, Ying-Cing; Kratochvil, Sven; Berndsen, Zachary T; Landais, Elise A; Kalyuzhniy, Oleksandr; Nair, Usha; Warner, John; Steichen, Jon M; Kalyuzhniy, Anton; Le, Amber; Pecetta, Simone; Perez, Manfredo; Kirsch, Kathrin; Weldon, Stephanie R; Falcone, Samantha; Himansu, Sunny; Carfi, Andrea; Sok, Devin; Ward, Andrew B; Schief, William R; Batista, Facundo D.
Afiliação
  • Melzi E; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Willis JR; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Res
  • Ma KM; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Res
  • Lin YC; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Kratochvil S; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Berndsen ZT; Department of Integrative, Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Landais EA; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Res
  • Kalyuzhniy O; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Res
  • Nair U; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Warner J; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Steichen JM; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Res
  • Kalyuzhniy A; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Res
  • Le A; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Res
  • Pecetta S; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Perez M; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Kirsch K; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Weldon SR; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Falcone S; Moderna Inc., Cambridge, MA 02139, USA.
  • Himansu S; Moderna Inc., Cambridge, MA 02139, USA.
  • Carfi A; Moderna Inc., Cambridge, MA 02139, USA.
  • Sok D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Res
  • Ward AB; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative, Structural and Computational Bi
  • Schief WR; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Scrip
  • Batista FD; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Immunology, Harvard Medical School, Boston, MA, USA; Department of Microbiology, Harvard Medical School, Boston, MA, USA. Electronic address: fbatista1@mgh.harvard.edu.
Immunity ; 55(11): 2168-2186.e6, 2022 11 08.
Article em En | MEDLINE | ID: mdl-36179690
ABSTRACT
Eliciting broadly neutralizing antibodies (bnAbs) is the core of HIV vaccine design. bnAbs specific to the V2-apex region of the HIV envelope acquire breadth and potency with modest somatic hypermutation, making them attractive vaccination targets. To evaluate Apex germline-targeting (ApexGT) vaccine candidates, we engineered knockin (KI) mouse models expressing the germline B cell receptor (BCR) of the bnAb PCT64. We found that high affinity of the ApexGT immunogen for PCT64-germline BCRs was necessary to specifically activate KI B cells at human physiological frequencies, recruit them to germinal centers, and select for mature bnAb mutations. Relative to protein, mRNA-encoded membrane-bound ApexGT immunization significantly increased activation and recruitment of PCT64 precursors to germinal centers and lowered their affinity threshold. We have thus developed additional models for HIV vaccine research, validated ApexGT immunogens for priming V2-apex bnAb precursors, and identified mRNA-LNP as a suitable approach to substantially improve the B cell response.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Vacinas contra a AIDS Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Vacinas contra a AIDS Idioma: En Ano de publicação: 2022 Tipo de documento: Article